Closed and Automated Cell Processing Using RoteaTM to Advance Cell Therapy

Sean Chang¹, Ian Fitzpatrick², Stephen Wilson², David James² and Xavier de Mollerat du Jeu¹

Lot release and

characterization


¹Thermo Fisher Scientific, 5781 Van Allen Way, Carlsbad, CA 92008 ²Scinogy Pty. Ltd, Melbourne, VIC, Australia

ABSTRACT

The manufacturing cost and complexity has been one of the biggest obstacles for delivering cell therapy products. Here we present RoteaTM, a compact closed automation system with counterflow centrifuge technology, which enables gentle cell separation, wash, and concentration with controllable input and output volumes. The 10ml chamber on the single use kit can sustain billions of cells as a fluidized bed and can be discharged multiple times if needed. The kit can be easily connected to other closed systems for upstream and downstream applications, for example Finesse bioreactor system, making Rotea a flexible modular instrument to fit in different workflows.

Using human primary T cells as a model, we have demonstrated that across different input and output settings, Rotea contributes superior processing time, recovery, and viability for cell wash, concentration, and buffer exchange as compared to manual centrifugation. More importantly, Rotea is capable of facilitating lymphocyte separation from leukopheresis products, which could shorten manufacturing time and cost of cell therapy products.

DEVELOPMENT STRATEGY AND RESULTS






Figure 1. Current cell therapy workflow. (A) Current processes rely heavily on cell isolation, wash, and concentrate. Automated processing in each step indicated in (B) could increase the efficiency and lower the cost of cell therapy manufacturing.




Figure 3. Consumable setup and protocol for PBMC isolation using Rotea. (A) Schematic diagram of Rotea single-use kit connecting with bags for input, output, and buffers. (B) Automated steps for Rotea PBMC isolation.

Figure 6. Consumable setup and protocol for T cell wash and concentrate using Rotea. (A) Schematic diagram of Rotea single-use kit connecting with bags for input, output, and buffers. (B) Automated steps for Rotea T cell wash and concentrate.

Flow rate


50ml/min

25ml/min

30ml/min

30ml/min

50ml/min






Figure 4. Rotea provides higher quality and efficiency of PBMC isolation as compared to **Ficoll separation.** (A and B) Rotea completes PBMC isolation in 30 minutes with thorough platelet and RBC depletion. (C and D) The viability, recovery and T cell composition from Rotea PBMC isolation are equal or better then Ficoll separation.




Figure 7. T cell wash and concentrate with controllable input and output scales. (A) Rotea chamber (left) accommodates more than $5x10^9$ T cells, and maintains high viability and recovery after wash. (B) Rotea precisely controls output volume as low as 5mL or less, therefore provides cell concentration as high as $1x10^8$ cells/mL in the output collection. (C) T cell composition remain the same after Rotea wash and concentrate.

CONCLUSIONS

 Rotea provides highly efficient PBMC isolation with high recovery and superior cell quality as compared to Ficoll separation.

- Scalable throughput- continuous processing of 0.1 to 20L
- Small minimum output volume- less than 5mL

Thaw cells

- **Flexible** programmable, multiple processing modes including cell separation, concentration and washing
- Universal kit (consumable) for different cell types and applications
- Compact and portable
- User friendly- easy to load, friendly user interface




Figure 5. T cells processed from Rotea exhibit similar quality as compare to Ficoll control throughout expansion. (A) The expansion rate of T cells after Rotea and Ficoll processing. (B) T cell composition, differentiation and exhaustion status are similar between Rotea and Ficoll samples after expansion.

- Rotea provides gentle and efficient cell wash and concentrate with flexible input and output volume.
- Rotea facilitates the whole cell therapy workflow from PBMC isolation all the way to cryopreservation.

TRADEMARKS/LICENSING

© 2019 Thermo Fisher Scientific Inc. All rights reserved.

All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.

For collaborations contact: Xavier de Mollerat du Jeu, PhD, Director of R&D, Life Science Group

xavier.demolleratdujeu@thermofisher.com

For Research Use Only. Not for use in diagnostic procedures.

ThermoFisher SCIENTIFIC